| Line Item | 2025-12-31 | Y/Y |
|---|---|---|
| Revenue | $0 | -100.0% |
| R&D Expense | $10.8M | +37.5% |
| SG&A Expense | $5.7M | +3.7% |
| Operating Income | -$12.8M | -384.5% |
| Pre-tax Income | -$12.1M | -314.1% |
| Income Tax | -$1.3M | -162.1% |
| Net Income | -$10.8M | -401.4% |
| EPS (Basic) | -$2.60 | -379.6% |
| EPS (Diluted) | -$2.64 | -403.4% |
| Line Item | 2025-12-31 | Y/Y |
|---|---|---|
| Cash & Equivalents | $8.7M | +129.3% |
| Short-term Investments | $8.4M | -63.5% |
| Accounts Receivable | $1.5M | +153.3% |
| Current Assets | $21.7M | -26.8% |
| Total Assets | $24.3M | -33.5% |
| Current Liabilities | $3.6M | -39.6% |
| Total Liabilities | $8.1M | -24.2% |
| Stockholders' Equity |
| Line Item | 2025-12-31 | Y/Y |
|---|---|---|
| Operating Cash Flow | -$10.0M | -216.4% |
| Capital Expenditures | $111K | +1670.9% |
| Investing Cash Flow | $14.4M | +163.7% |
| Financing Cash Flow | $266K | -98.3% |
| Free Cash Flow | -$10.1M | -217.8% |
| $16.1M |
| -37.4% |